Brand names: Potassium Phosphates
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS Potassium phosphates injection is contraindicated in patients with: Hyperkalemia [see Warning and Precautions (5.3) ]. Severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or end stage renal disease [see Warning and Precautions (5.3) ] . Hyperphosphatemia [see Warning and Precautions (5.4) ]. Hypercalcemia or significant hypocalcemia [see Warning and Precautions (5.4) ] . Hyperkalemia. ( 4 ) Hyperphosphatemia. ( 4 ) Hypercalcemia or significant hypocalcemia. ( 4 ) Severe renal impairment (eGFR less than 30 mL/min/1.73 m 2 ) or end stage renal disease. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Administration of the recommended dose of potassium phosphates injection is not expected to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with potassium phosphates injection. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and/or Embryo-Fetal Risk Phosphorus is an essential mineral element. Parenteral supplementation with potassium phosphates should be considered if a pregnant woman’s requirements cannot be fulfilled by oral or enteral intake.
6 interactions on record
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic
Concurrent use increases risk of severe and potentially fatal hyperkalemia. Avoid use; if unavoidable, closely monitor serum potassium concentrations.
Source: NLP:potassium phosphate, monobasic potassium phosphate, dibasic